Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.72 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.72 |
| ▸ | MC4R | P32245 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD4 | P21917 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP4 | P49662 | 1/20 | 0.55 |
| ▸ | CASP5 | P51878 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2980328 | 0.98 | CHRNB2 (0.70) | CHRNB2CHRNA4MC4RKDM4EALDH1A1 | |
| SCHEMBL16026435 | 0.91 | CHRNB2 (0.85) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL10294632 | 0.86 | CHRNB2 (0.72) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL29615719 | 0.86 | CHRNB2 (0.62) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL15800693 | 0.86 | CHRNB2 (0.77) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL14194084 | 0.85 | HRH3 (0.55) | CHRNB2CHRNA4KDM4EALDH1A1 | |
| SCHEMBL30711590 | 0.84 | CHRNB2 (0.93) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL1538320 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| N-(3-Pyridylmethyl)Pyrrolidine SCHEMBL30341021 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 | |
| SCHEMBL7194677 | 0.83 | CHRNB2 (0.68) | CHRNB2CHRNA4KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2025-01-14 | — | — | US | claimed |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | DONG A SOCIO HOLDINGS CO LTD (KR) | 2023-01-05 | — | — | US | claimed |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | NIPPON SHINYAKU CO., LTD. (JP) | 2025-12-30 | — | — | US | disclosed |
| CN-119371410-A | Chromone spiro compound and preparation method and application thereof | 中国药科大学 | 2025-01-28 | — | — | CN | disclosed |
| US-20240092791-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-21 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| EP-0804428-B1 | BIS-SULFONAMIDE HYDROXYETHYLAMINO RETROVIRAL PROTEASE INHIBITORS | SEARLE LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| US-7297793-B2 | Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors | G.D. SEARLE, LLC (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| WO-2004101507-A2 | N-SULPHONYLATED AMINO ACID DERIVATIVES AND USE THEREOF AS MATRIPTASE INHIBITORS | CURACYTE CHEMISTRY GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | CHRNB2 4388/4885CHRNA4 4700/4885MC4R 2519/4885 |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | CHRNB2 4663/4885CHRNA4 4859/4885MC4R 2367/4885 |
| US-12195446-B2 | Heteroaryl compounds and their use as therapeutic drugs | MERTK, ERBB2, SRC | CHRNB2 3330/4885CHRNA4 3770/4885MC4R 509/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | CHRNB2 517/4885CHRNA4 287/4885MC4R 435/4885 |
| US-12509424-B2 | Compound and composition as PDGF receptor kinase inhibitor | PDGFRA, PDGFRB, PDGFA | CHRNB2 2236/4885CHRNA4 1792/4885MC4R 2281/4885 |
| US-20230002353-A1 | HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS | MERTK, ERBB2, SRC | CHRNB2 3330/4885CHRNA4 3770/4885MC4R 509/4885 |
| US-20240092791-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | CHRNB2 1864/4885CHRNA4 1999/4885MC4R 4302/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | CHRNB2 246/4885CHRNA4 367/4885MC4R 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.